Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets.

Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, Geyer FC, van Kouwenhove M, Kreike B, Mackay A, Ashworth A, van de Vijver MJ, Reis-Filho JS.

Oncogene. 2010 Apr 8;29(14):2013-23. doi: 10.1038/onc.2009.489. Epub 2010 Jan 18.

2.

Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells.

Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, Dirbas FM, Somlo G, Pera RA, Lao K, Clarke MF.

Cell. 2009 Aug 7;138(3):592-603. doi: 10.1016/j.cell.2009.07.011.

3.

Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours.

Albergaria A, Paredes J, Sousa B, Milanezi F, Carneiro V, Bastos J, Costa S, Vieira D, Lopes N, Lam EW, Lunet N, Schmitt F.

Breast Cancer Res. 2009;11(3):R40. doi: 10.1186/bcr2327. Epub 2009 Jun 23.

4.

A complex role for FGF-2 in self-renewal, survival, and adhesion of human embryonic stem cells.

Eiselleova L, Matulka K, Kriz V, Kunova M, Schmidtova Z, Neradil J, Tichy B, Dvorakova D, Pospisilova S, Hampl A, Dvorak P.

Stem Cells. 2009 Aug;27(8):1847-57. doi: 10.1002/stem.128.

5.

Syndecan-4-expressing muscle progenitor cells in the SP engraft as satellite cells during muscle regeneration.

Tanaka KK, Hall JK, Troy AA, Cornelison DD, Majka SM, Olwin BB.

Cell Stem Cell. 2009 Mar 6;4(3):217-25. doi: 10.1016/j.stem.2009.01.016.

6.

Association of reactive oxygen species levels and radioresistance in cancer stem cells.

Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, Clarke MF.

Nature. 2009 Apr 9;458(7239):780-3. doi: 10.1038/nature07733.

7.

Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma.

Read TA, Fogarty MP, Markant SL, McLendon RE, Wei Z, Ellison DW, Febbo PG, Wechsler-Reya RJ.

Cancer Cell. 2009 Feb 3;15(2):135-47. doi: 10.1016/j.ccr.2008.12.016. Erratum in: Cancer Cell. 2009 Sep 8;16(3):267.

8.

Crypt stem cells as the cells-of-origin of intestinal cancer.

Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, Danenberg E, Clarke AR, Sansom OJ, Clevers H.

Nature. 2009 Jan 29;457(7229):608-11. doi: 10.1038/nature07602. Epub 2008 Dec 17.

PMID:
19092804
9.

Efficient tumour formation by single human melanoma cells.

Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ.

Nature. 2008 Dec 4;456(7222):593-8. doi: 10.1038/nature07567.

10.

Genetic mosaic analysis reveals FGF receptor 2 function in terminal end buds during mammary gland branching morphogenesis.

Lu P, Ewald AJ, Martin GR, Werb Z.

Dev Biol. 2008 Sep 1;321(1):77-87. doi: 10.1016/j.ydbio.2008.06.005. Epub 2008 Jun 13.

11.

Identification of tumor-initiating cells in a p53-null mouse model of breast cancer.

Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D, Medina D, Tsimelzon A, Hilsenbeck S, Green JE, Michalowska AM, Rosen JM.

Cancer Res. 2008 Jun 15;68(12):4674-82. doi: 10.1158/0008-5472.CAN-07-6353.

12.

Drug-sensitive FGFR2 mutations in endometrial carcinoma.

Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, Nicoletti R, Winckler W, Grewal R, Hanna M, Wyhs N, Ziaugra L, Richter DJ, Trovik J, Engelsen IB, Stefansson IM, Fennell T, Cibulskis K, Zody MC, Akslen LA, Gabriel S, Wong KK, Sellers WR, Meyerson M, Greulich H.

Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8713-7. doi: 10.1073/pnas.0803379105. Epub 2008 Jun 13.

13.

The epithelial-mesenchymal transition generates cells with properties of stem cells.

Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA.

Cell. 2008 May 16;133(4):704-15. doi: 10.1016/j.cell.2008.03.027.

14.

Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer.

Meyer KB, Maia AT, O'Reilly M, Teschendorff AE, Chin SF, Caldas C, Ponder BA.

PLoS Biol. 2008 May 6;6(5):e108. doi: 10.1371/journal.pbio.0060108.

15.

Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer.

Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, Jonsson GF, Jakobsdottir M, Bergthorsson JT, Gudmundsson J, Aben KK, Strobbe LJ, Swinkels DW, van Engelenburg KC, Henderson BE, Kolonel LN, Le Marchand L, Millastre E, Andres R, Saez B, Lambea J, Godino J, Polo E, Tres A, Picelli S, Rantala J, Margolin S, Jonsson T, Sigurdsson H, Jonsdottir T, Hrafnkelsson J, Johannsson J, Sveinsson T, Myrdal G, Grimsson HN, Sveinsdottir SG, Alexiusdottir K, Saemundsdottir J, Sigurdsson A, Kostic J, Gudmundsson L, Kristjansson K, Masson G, Fackenthal JD, Adebamowo C, Ogundiran T, Olopade OI, Haiman CA, Lindblom A, Mayordomo JI, Kiemeney LA, Gulcher JR, Rafnar T, Thorsteinsdottir U, Johannsson OT, Kong A, Stefansson K.

Nat Genet. 2008 Jun;40(6):703-6. doi: 10.1038/ng.131. Epub 2008 Apr 27.

PMID:
18438407
16.

A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors.

Sarker D, Molife R, Evans TR, Hardie M, Marriott C, Butzberger-Zimmerli P, Morrison R, Fox JA, Heise C, Louie S, Aziz N, Garzon F, Michelson G, Judson IR, Jadayel D, Braendle E, de Bono JS.

Clin Cancer Res. 2008 Apr 1;14(7):2075-81. doi: 10.1158/1078-0432.CCR-07-1466.

17.

Terminal end bud maintenance in mammary gland is dependent upon FGFR2b signaling.

Parsa S, Ramasamy SK, De Langhe S, Gupte VV, Haigh JJ, Medina D, Bellusci S.

Dev Biol. 2008 May 1;317(1):121-31. doi: 10.1016/j.ydbio.2008.02.014. Epub 2008 Feb 21.

18.

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.

Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G.

Cell Stem Cell. 2007 Nov;1(5):555-67. doi: 10.1016/j.stem.2007.08.014.

19.

Significance of CD90+ cancer stem cells in human liver cancer.

Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT, Fan ST.

Cancer Cell. 2008 Feb;13(2):153-66. doi: 10.1016/j.ccr.2008.01.013.

20.

GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model.

Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ, Pai SY, Ho IC, Werb Z.

Cancer Cell. 2008 Feb;13(2):141-52. doi: 10.1016/j.ccr.2008.01.011.

Supplemental Content

Support Center